论文信息 - Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use - 字舞流文

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

E. Hoster | A. Mackensen | U. Holtick | F. Locke | M. Subklewe | C. Schmidt | V. Jurinovic | O. Penack | P. Gödel | G. Iacoboni | K. Rejeski | V. Blumenberg | M. Jain | P. Barba | R. Mhaskar | A. Perez | O. Albanyan | G. Johnson | B. Arciola | S. Kharboutli | M. von Bergwelt | K. Patel | Anthony C. Wood | L. Frölich | J. Ackermann | Lars Bullinger | Veit L Bücklein